Compare AbCellera Biologics Inc (ABCL) vs Centrus Energy Corp (LEU) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Centrus Energy (LEU) trades at $174.23, up 7.46% today, with mixed technical signals showing neutral momentum. The company reported strong Q1 2026 earnings beat but faces valuation concerns with a P/E of 63.36. Recent catalysts include a $900 million DOE contract and inclusion in the S&P SmallCap 600 index, positioning LEU as the sole U.S.-licensed HALEU producer amid growing nuclear energy demand.

LEU offers exposure to U.S. nuclear fuel supply chain growth with $3.9 billion contracted backlog, but high valuation and execution risks warrant caution. Analyst consensus targets $219.50 (26% upside) with no sell ratings, though recent earnings misses and declining 2026 profit margins highlight operational challenges. The stock's premium valuation requires sustained contract execution and margin improvement to justify current levels.